Unfortunately, however, besides the combinatorial activity of the Eg5 inhibitor, filanesib, with bortezomab and dexamethasone in multiple myeloma [75,239], kinesin inhibitors have yielded low or no objective response rates in advanced cancer patients. Here, KIF11 is linked to plasma cell myeloma.